Danaher is trading lower as the market continues to digest its pending acquisition of Masimo in an all-cash transaction valued at about $9.9 billion, with Masimo shareholders slated to receive $180.00 per share. The deal has kept pressure on Danaher’s equity as investors weigh the near-term financing and execution overhang typically associated with large, debt-funded healthcare transactions.

With Masimo expected to become an operating company within Danaher’s Diagnostics segment after closing (targeted for the second half of 2026), the transaction introduces integration complexity and higher balance-sheet leverage risk. That has also raised governance and deal-risk scrutiny in the market, which can translate into multiple compression when investors demand a higher risk premium for execution uncertainty.

Danaher’s most recent outlook calls for 2026 non-GAAP core revenue growth of 3% to 6% and adjusted diluted EPS of $8.35 to $8.50, a range that implies the stock’s downside can accelerate on any incremental sign that end-market recovery is slower than expected. In this setup, even without new headlines, the combination of a large pending deal and a measured growth outlook can amplify day-to-day downside moves as investors reposition.